Loading
New short-read sequencing platforms from Ultima Genomics, Element Biosciences, Roche and MGI compete with Illumina by cutting the cost per gigabase, with Ultima claiming a genome under 100 dollars. Cheaper reads make whole-genome tumour-normal sequencing and deep ctDNA testing affordable in principle, but clinical assays must be revalidated and Illumina's installed base still dominates.
Ultima Genomics (UG 100, sub-$100 genome claims), Element Biosciences (AVITI), Roche's sequencing-by-expansion (SBX, launched 2025-26), MGI/Complete Genomics, and Singular Genomics compete with Illumina's NovaSeq X. Lower cost per gigabase enables whole-genome tumour-normal sequencing, high-depth ctDNA, and single-cell studies at scale; clinical validation and installed base still favour Illumina.
Massively parallel sequencing-by-synthesis or expansion chemistry with optical or electronic readout on flow cells or open wafers.
Query for this technology: (TITLE:"New short-read sequencing platforms" OR ABSTRACT:"New short-read sequencing platforms") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about New short-read sequencing platforms, not a curated reading list.
Shares Illumina, Whole-exome & whole-genome sequencing, Comprehensive genomic profiling, Liquid biopsy (ctDNA) and the tag supporting.
Shares BIOSECURE Act and the tag supporting.
Shares Roche / Genentech, Liquid biopsy (ctDNA) and the tag supporting.
Shares BIOSECURE Act and the tag supporting.
Shares Roche / Genentech, Comprehensive genomic profiling and the tag supporting.
Shares Comprehensive genomic profiling and the tag supporting.
Shares Comprehensive genomic profiling and the tag supporting.
Shares Liquid biopsy (ctDNA) and the tag supporting.